Loading
Horizon Therapeutics Public Ltd Co Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Clayton Sean M., was filed 08 Aug 2022.
Horizon Therapeutics Public Ltd Co: what insiders have been doing
Horizon Therapeutics Public Ltd Co, classified in the Healthcare & Pharma sector, is a listed company based in Ireland, Ireland, founded in 2005. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Horizon Therapeutics Public Ltd Co in twelve months, the latest record being from 6 October 2023.
Our records for Horizon Therapeutics Public Ltd Co go back to 2016, with 2 purchases and 259 sales on the open market in total.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
1,054
Thresholds
n/a
Buy Volume
€135,675
2 ops. · all time
Sell Volume
€314M
259 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$3.1B
Gross profitUS$2.3B75% margin
Net incomeUS$449M14.4% margin
Last declaration on 6 October 2023
Declarations1,054 total
47,670 shares@ US$116.5046.5% of flowOrdinary SharesSEC:0001209191-23-052372:1
18,655 shares@ US$116.5013.0% of flowOrdinary SharesSEC:0001209191-23-052367:1
107,739 shares@ US$116.504.0% of flowOrdinary SharesSEC:0001209191-23-052361:1
100,300 shares@ US$116.503.7% of flowOrdinary SharesSEC:0001209191-23-052361:2
49,935 shares@ US$116.501.9% of flowOrdinary SharesSEC:0001209191-23-052361:3
55,953 shares@ US$116.5030.0% of flowOrdinary SharesSEC:0001209191-23-052376:1
10,000 shares@ US$116.505.4% of flowOrdinary SharesSEC:0001209191-23-052376:2
105,808 shares@ US$116.5019.5% of flowOrdinary SharesSEC:0001209191-23-052358:1
80,944 shares@ US$116.5014.9% of flowOrdinary SharesSEC:0001209191-23-052358:2
45,352 shares@ US$116.508.3% of flowOrdinary SharesSEC:0001209191-23-052358:3
9,306 shares@ US$116.5035.5% of flowOrdinary SharesSEC:0001209191-23-052375:1
20,279 shares@ US$116.5035.1% of flowOrdinary SharesSEC:0001209191-23-052374:1
23,638 shares@ US$116.5028.3% of flowOrdinary SharesSEC:0001209191-23-052370:1
745 shares@ US$116.504.8% of flowOrdinary SharesSEC:0001209191-23-052359:1
36,609 shares@ US$116.5037.2% of flowOrdinary SharesSEC:0001209191-23-052371:1
7,873 shares@ US$116.508.0% of flowOrdinary SharesSEC:0001209191-23-052371:2
48,031 shares@ US$116.5037.5% of flowOrdinary SharesSEC:0001209191-23-052373:1
10,000 shares@ US$116.507.8% of flowOrdinary SharesSEC:0001209191-23-052373:2
25,672 shares@ US$116.50100.0% of flowOrdinary SharesSEC:0001209191-23-052374:0
2,655 shares@ US$116.505.9% of flowOrdinary SharesSEC:0001209191-23-052358:0
14,575 shares@ US$116.5050.9% of flowOrdinary SharesSEC:0001209191-23-052363:0
44,546 shares@ US$116.5092.1% of flowOrdinary SharesSEC:0001209191-23-052371:0
33,156 shares@ US$116.5096.4% of flowOrdinary SharesSEC:0001209191-23-052370:0
7,655 shares@ US$116.5094.6% of flowOrdinary SharesSEC:0001209191-23-052359:0
31,915 shares@ US$116.5094.4% of flowOrdinary SharesSEC:0001209191-23-052372:0
25 of 1054 declarations
About Horizon Therapeutics Public Ltd Co
Horizon Therapeutics Public Ltd Co (ticker HZNP) was a U.S.-focused biopharmaceutical company listed on the Nasdaq in the United States and built around specialty medicines for rare, autoimmune, and severe inflammatory diseases. The company was founded in 2005 in Illinois and later moved its legal headquarters to Ireland through a tax inversion, while its commercial footprint and revenue base remained heavily concentrated in the U.S. For investors, Horizon is best understood as a highly focused specialty pharma platform rather than a broad diversified pharmaceutical group.
Its business model centered on discovering, developing, and commercializing medicines for medically underserved patient populations. Horizon’s core commercial franchises were TEPEZZA for thyroid eye disease, KRYSTEXXA for chronic refractory gout, and UPLIZNA for certain rare autoimmune indications. The portfolio also included RAVICTI, PROCYSBI, ACTIMMUNE, PENNSAID 2%, and DUEXIS, reflecting a mix of growth assets and established specialty products. In its 2022 annual report, Horizon described itself as a global biotechnology company targeting critical needs in rare, autoimmune, and severe inflammatory diseases, with a portfolio that was meaningfully international even though the business remained overwhelmingly U.S.-driven.
Read moreShow less
From a competitive standpoint, Horizon’s edge came from deep expertise in specialty commercialization: reaching disease specialists, building physician awareness, supporting patient identification and adherence, and expanding labels through clinical data generation. That model gave Horizon a stronger moat than many small-cap biotechs, because its products addressed narrow, high-unmet-need markets where execution and clinical differentiation matter more than mass-market scale. At the same time, the company was exposed to concentration risk because a limited number of molecules accounted for much of its growth and investor attention. Prior to its takeout, TEPEZZA, KRYSTEXXA, and UPLIZNA were the main revenue drivers and the clearest indicators of platform strength.
The most important recent corporate event is that Amgen announced and completed the acquisition of Horizon, closing on October 6, 2023, for approximately $27.8 billion in cash. As a result, Horizon is no longer an independently traded company, and references to HZNP in SEC Form 4 filings are mainly historical insider-transaction records from before the transaction closed. In strategic terms, Horizon became a notable rare-disease success story that created substantial value through specialty product commercialization before being absorbed by a larger U.S. pharmaceutical company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1492426/000095017023005337/hznp-20221231.htm?utm_source=openai))
